GlassScriptPhysician profile
Gregorio Uy Tan
NPI 1316926751
$1,421.13
in general payments reported to CMS, 2019-2025
19 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $5.30 · 2021: $26.99 · 2022: $84.84 · 2023: $378 · 2024: $116 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $288.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $263.68 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $90.43 | 2019-2024 | Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.35 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $86.48 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $86.38 | 2019-2023 | Repatha |
| Aurinia Pharma U.S., INC. | $85.93 | 2023 | Lupkynis |
| Abbott Laboratories | $79.87 | 2019-2024 | Amplatzer Talisman |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.13 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $50.47 | 2022-2023 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $38.32 | 2022-2023 | Watchman Access System |
| Zoll Circulation INC | $36.91 | 2023-2024 | Catheter, Downstream Cartridge, Therox Ds2 Console |
| Sanofi-Aventis U.S. LLC | $32.13 | 2019 | |
| Novo Nordisk INC | $27.69 | 2025 | Wegovy |
| Atricure, INC. | $26.76 | 2025 | Atriclip Laa Exclusion System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.99 | 2025 | |
| Glaxosmithkline, LLC. | $14.73 | 2025 | Shingrix |
| Cardinal Health 200 LLC | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregorio Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.